ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events Dose level 2 prevented disease progression and reduced ...

WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. This piece also marks part ...

Long-term use of continuous positive airway pressure (CPAP) slowed the progression of eye disease in sleep apnea patients with non-proliferative diabetic retinopathy, a small randomized study showed, ...

STOCKHOLM — At the American Society of Retina Specialists (ASRS) 2024 Annual Meeting, researchers discussed how insights into potential risk factors and new treatments could improve outcomes for ...

LONG BEACH, Calif. -- Two different ocular implants eluting an endothelin antagonist showed early promise for slowing diabetic eye disease, according to two small studies reported here. In a ...

Credit: Genentech. Susvimo is indicated for intravitreal use via the Susvimo ocular implant. For patients with diabetic retinopathy, refills of Susvimo are administered every 36 weeks (approximately 9 ...

OcuTerra Therapeutics’ investigational eye drops failed to improve disease severity or progression in a phase 2 diabetic retinopathy trial, prompting the Boston-based biotech to look at strategic ...

Session Title: Diabetic Retinopathy Symposium 2 Session Date/Time: Thursday, July 18th 10:47 – 10:51 AM CEST Presenter: Dilsher S. Dhoot, MD About the HELIOS studyThe Phase 1 HELIOS trial is a ...